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 Abstract                                                                                                            
Background: Herbal medical compounds and their major 
constituent have been used in the management and treatment of 
opioid withdrawal syndrome and pain. This study was carried 
out to clarify the effect of curcumin, the major compound of 
turmeric, on morphine withdrawal syndrome in mouse model and 
its possible mechanisms of pain relieving activity by assessing 
in writhing test as a model of visceral pain. 
Methods: Due to two separate protocols (withdrawal syndrome 
and pain), 144 male albino mice were divided in two major 
groups. In withdrawal syndrome group, test effect of various 
dosages of curcumin (10, 20, and 40 mg/kg) was assessed on 
withdrawal signs and compared with positive and negative control 
and standard treatment (clonidine 0.4 mg/kg) groups. In pain 
groups, to determine the mechanism of pain relieving activity of 
curcumin, various dosages of curcumin (10, 20, and 40 mg/kg) 
in three separated groups, were used against acetic acid induced 
writhing (which is a constriction) test. The most effective dose 
(40 mg/kg) was used in writhing test and compared with groups 
pretreated with antagonist of major neurotransmitters involved in 
pain; and compared with group pretreated with vehicle (DMSO, 
0.05%) as control.
Results: Curcumin attenuates withdrawal syndrome in a dose 
dependent manner in comparison with the dependent positive 
control group (P<0.05). It also indicated that pretreatment 
with naloxone and cyproheptadine significantly attenuate 
antinociception effect of curcumin (P<0.05).
Conclusion: This study advocate that antinociception of 
curcumin was mediated by opioidergic and adrenergic system. 
Please cite this article as: Motaghinejad M, Bangash MY, Hosseini P, Karimian 
SM, Motaghinejad O. Attenuation of Morphine Withdrawal Syndrome by Various 
Dosages of Curcumin in Comparison with Clonidine in Mouse: Possible Mechanism. 
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 Introduction                                                                                          
Herbal medical compounds are considered as major sources of new 
chemical medications with potential therapeutic activities. In recent 
years, these natural medical compounds and their flavonoids have 
been used in multiple mental disorders. One of these disorders is 
addiction.1 Drug dependency is a major problem all over the world. 
Many studies are carried out on opioidergic and non-opioidergic 
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drugs, which can attenuate morphine withdrawal 
symptoms and pain suppression during withdrawal 
syndrome period. Most of these medications interact 
with dopaminergic, adrenergic, serotonergic, 
opioidergic, histaminergic, and purinergic systems.2-5
Usage of herbal medicine for the management 
of pain and attenuation of withdrawal symptoms 
has been developed in recent years, and many 
studies have been carried out to evaluate the 
effects of these medications on different methods 
of antinociception tests.6 One of the important 
herbal medicines is curcumin. Curcumin is a 
yellow pigment and one of the major constituents 
of turmeric rhizomes. This fraction has important 
medicinal and pharmacological properties. 
Extract of rhizomes of Curcuma longa is a major 
constituent of Miao-Yao-San and Jieyuwan, the 
traditional Chinese herbal medicines, which has 
been effectively used in the treatment of pain, 
stress, depression, drug dependency, and related 
disorders in China.7-9
Previous studies have shown that 
curcumin has antioxidant, anti-inflammatory, 
immunomodulatory, anticancer, and 
neuroprotective properties.10-14 Several studies 
indicated that curcumin has antinociceptive 
effect. Intraperitoneal (IP) injection of curcumin, 
attenuates pain perception in both visceral 
nociception induced by acetic acid and tail-
flick test. However, the mechanisms of this 
antinociception activity is not clear.15  Previous 
studies indicated that naloxone (opioid receptor 
antagonist) or methysergide (5-HT serotonergic 
receptor antagonist) decrease curcumin 
antinociceptive activity in acetic acid induced 
visceral pain. Oral application of curcumin 
alleviates the number of abdominal construction 
in writhing test. These studies also showed 
that endogenous analgesic opioid system is 
involved in the curcumin-induced antinociception 
properties in rats.16,17
A study showed that single dose and chronic 
oral administrations of curcumin attenuates 
corneal pain in the presence and absence of 
morphine, in which curcumin enhances morphine-
induced antinociception effect.18
The results of another study showed that 
chronic treatment with curcumin, decreases 
thermal hyperalgesia and increases latency phase 
of pain response in diabetic neuropathic pain 
model of mouse.8 Oral administration of curcumin 
decreases the latency time of pain induced by an 
intraplantar injection of formalin in rats.16 
Also IP administration of curcumin attenuates 
face wiping behavior in acute and tonic phase 
of orofacial pain which was induced by formalin 
in rat.19 Long term administration of curcumin 
attenuates lipopolysaccharide-induced 
nociception in mice.20 
Regarding these effects, the aim of this 
study is to determine the effect of pain relieving 
activity of curcumin by two different protocols. 
First, assessment of the effect of curcumin in the 
treatment and management of dependency to 
morphine as a standard opioid medication, and then 
to determine the mechanism of its antinociception 
by acetic acid induced writhing test.
 Materials and Methods                                                                                     
Drugs
1: Curcumin (Sigma–Aldrich Inc., St Louis MO, 
USA), 2: Acetic acid (as a nociceptive agent), 3: 
Naloxone (as an opioidergic receptor antagonist), 
4: Cyproheptadine (as a serotonergic receptor 
antagonist), 5: Phentolamine (as an adrenergic 
receptor antagonist), 6: Chlorpheniramine (as 
a H1-histaminergic receptor antagonist), 7: 
Cimetidine (as a H2-histaminergic receptor 
antagonist), 8: Metoclopramide (as a dopaminergic 
receptor antagonist), 9: Indometacin.
All the mentioned drugs were from Sigma–
Aldrich Inc. (St Louis, MO, USA) and were 
dissolved in dimethyl sulfoxide 5% (DMSO). We 
also used morphine sulphate (Temad Co. Tehran, 
Iran) and clonidine hydrochloride (Tolid Daru Co., 
Tehran, Iran). All agents were freshly prepared 
just before use. 
Animals
144 Male albino mice weighing 30-35 g were 
used in this study. Animals were kept in 22ºC±2 
temperature and light controlled room under a 
12 h light and dark cycle. Food and water were 
available ad libitum. The animals were allowed 
to adapt to the laboratory environment at least 
2 hours before testing and they were used only 
once. All experimental procedures followed the 
guidelines on Ethical Standards for experiment 
on pain in animals and carried out according to 
a protocol approved by the local Animal Ethics 
Committee. These animals were randomly divided 
in two major groups: (1) Morphine withdrawal 
syndrome protocol and (2) Writhing test protocol. 
Each group was divided into subgroups (8 per 
subgroup) as described below.
Morphine Withdrawal Syndrome Protocol
48 mice were divided randomly into 6 groups: 
● Group I: as “Negative control group” 
(independent) received normal saline for 12 days.
● Group II: as “Positive control group” 
(dependent) received morphine with an increasing 
dosage for the first 6 days and afterwards received 
the highest dose of morphine for the next 6 days.
● Group III: received morphine with an 
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increasing dosage for the first 6 days and 
afterwards received clonidine hydrochloride 
injections 0.4 mg/kg, concurrently with morphine 
once a day from days 6 to 12. 
● Groups IV, V, and VI: received morphine 
for 6 days and then curcumin was injected with 
doses of 10, 20 and 40 mg/kg respectively and 
concurrently with morphine once a day from days 
6 to 12.
Induction of Morphine Dependency
Morphine dependency induced by the 
injection of morphine 20-45 mg/kg in 5 groups 
(out of 6). Morphine was injected subcutaneously 
with an increasing dosage manner for 6 days. 
This method of morphine withdrawal syndrome 
induction was done on the basis and similar to 
the previous studies.3,21
Induction and Evaluation of Morphine Withdrawal 
Syndrome
On the 13th day, all animals in each group 
were injected with naloxone 3 mg/kg, and 
behaviors of each animal were recorded by a 
camera. Recorded behaviors included jumping, 
headshake, wet dog shake, forepaw tremor, 
writhing, walking sniffing, sniffing, penile liking, 
rearing, chewing, body grooming, face wiping, 
swallowing, teeth chattering. Following data 
processing, the count of each behavior was 
registered and divided by their weighing factor 
to obtain a single value representing the Total 
Withdrawal Score (TWS) (table 1). All behavioral 
signs were measured on the basis of previous 
studies.3,21
Writhing Test Protocol
This test is based on inducing nociception 
by intra peritoneal injection of 10 ml/kg acetic 
acid (0.8%). The measurement of severity 
of nociception is by counting the number of 
abdominal constrictions known as writhing. The 
total number of writhing was recorded by camera 
during 30 minutes after the injection of acetic 
acid. Antinociception activity of the treatment 
was expressed as the percentage of inhibition 
of abdominal constrictions in each group by the 
below formula: 
(Treated mean-vehicle mean×100)/Vehicle mean
This method of antinociceptive evaluation 
was done on the basis of previous studies.22,23 
In addition, the onset of the first writhing was 
recorded as the latency time. 
Grouping of Animals
96 male mice were randomly divided into 12 
groups:
● Groups I and II: (control and indometacin 
treatment groups) received normal saline 0.1 ml/
mice and indometacin 5 mg/kg, 15 minutes before 
injecting acetic acid, respectively.
● Groups III, IV, and V: (under treatment with 
various dosages of curcumin) received curcumin 
with doses of 10, 20 and 40 mg/kg, 15 minutes 
before injecting acetic acid, respectively. 
● Groups VI, VII, VIII, IX, X, and XI: (treated 
with antagonist of the major neurotransmitters 
involved in pain). These groups were pretreated 
with either dopaminergic receptor antagonist 
(metoclopramide, 2 mg/kg), adrenergic receptor 
antagonist (phentolamine, 20 mg/kg), serotonergic 
receptor antagonist (cyproheptadine, 4 mg/
kg), opioid receptor antagonist (naloxone, 2 
mg/kg), histamine type 2 receptor antagonist 
(cimetidine, 10 mg/kg) and type 1 histamine 
receptor antagonist (chlorpheniramine, 10 mg/kg), 
respectively. 15 minutes later, all animals in these 
groups received dominant doses of Curcumin 
40 mg/kg, and after a further 15 minutes, they 
were injected with acetic acid 0.8% 10 ml/kg for 
visceral pain groups. 
● Group XII: as the control group, initially 
received vehicle (DMSO, 0.05% as 10 ml/kg) 
and after 15 minutes received curcumin 40 mg/
kg and 15 minutes later were injected with acetic 
acid 0.8%, 10 ml/kg for visceral pain induction. 
Statistical Analysis
All data were analyzed by SPSS statistic 
software for both protocols.
● Withdrawal Syndrome Protocol Data 
Analysis
The data were presented as mean±SEM. 
Differences between control and 
Table 1: Weighing factors (WFs) of different withdrawal signs of morphine in the mouse
Behavior WF Behavior WF
1) Jumping 4 9) Body grooming 10
2) Head shake  5 10) Face wiping 10
3) Wet dog shake 5 11) Swallowing 10
4) Paw tremor 5 12) Teeth chattering 10
5) Writhing 5 13) Dysphoria 10
6) Walking sniffing                        5 14) Rearing 20
7) Sniffing 5 15) Chewing 20
8) Penile licking 5 -------- --------
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morphine-dependent groups were evaluated by 
unpaired Student’s t test. In addition, differences 
among groups receiving various dosages of 
curcumin were first compared by one–way 
analysis of variance (ANOVA) with Tukey’s post-
hoc test. P value less than 0.05 was considered 
to indicate statistical significance.
● Writhing Test Protocol Data Analysis:
The data were presented as the mean±SEM. 
Differences between various dosages of curcumin 
and control or indometacin were analyzed 
separately by unpaired Student’s t test. In addition, 
differences between each group of pretreated 
with antagonists and curcumin dominant dose 
(40 mg/kg) or vehicle analyzed separately by 
unpaired Student’s t test. P value less than 0.05 
was considered to indicate statistical significance.
 Results                                                                                     
Total Withdrawal Score (TWS) Results 
Treatment of animals with naloxone: TWS 
in control morphine dependent group was 
50.1±2.2 and in negative control group (with no 
dependency) was 19.1±1.1, which was significantly 
different (P≤0.05) (figure 1). 
Administration of clonidine (dependent, group 
III) decreased the TWS to 24.1±0.9. In comparison 
with positive control group (dependent), this was 
significant but such attenuation is not statistically 
significant in comparison with the negative control 
(independent) group (P<0.05) (figure 1).
Administration of curcumin with three doses 
(40, 20, and 10 mg/kg) decreased TWS to 
22.1±0.9, 25.9±1.2, 27.1±1.1, respectively. These 
attenuations were significant in comparison with 
positive control (dependent) group and there 
was no significant difference with normal group 
(P<0.05) (figure 2).
Evaluation of Antinociceptive Effects of Curcumin 
in Writhing Test 
The results showed that various dosages 
of curcumin cause significant reduction in 
pain response in a dose-dependent manner in 
comparison with the control group (P<0.05). 
Figure 1: Total  withdrawal score (TWS) in negative control group (independent), treatment group by clonidine (dependent) 
compared with positive control group (dependent). Data are mean±SEM. N=8 per group; *(P<0.05) compared with groups of 
negative control and treatment by clonidine.                                                                                                                                                
Figure 2: Total withdrawal score (TWS) in mice at three doses of curcumin, compared with positive control group (dependent). 
Data are mean±SEM. N=8 per group; *(P<0.05) compared with groups under treatment by various doses of curcumin.                                         
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Indometacin, in comparison with the control 
group, significantly decreased the number of 
writhing (P<0.05). The percentage of inhibition of 
writhing response exhibited by curcumin extract 
at doses 10, 20 and 40 mg/kg were 23%, 26%, 
and 39% respectively. Note that, indometacin 
inhibited the writhing response by 74% (table 2).
Effect of Various Antagonists of Neurotransmitter 
on the Antinociceptive Action of Curcumin 
The results showed that 40 mg/kg of curcumin, 
induced a significant reduction in pain response 
(33 %) compared with control group (DMSO 5%) 
(P<0.05). The data also showed that, pretreatment 
with naloxone and cyproheptadine (as opioidergic) 
and serotonergic system antagonist, significantly 
reduces the antinociceptive effect of curcumin. 
Such reduction was significant in comparison with 
curcumin (40 mg/kg) group (P<0.05). Pretreatment 
with phentolamine (adrenergic antagonist), 
chlorpheniramine (H1-histaminergic antagonist), 
cimetidine (H2-histaminergic antagonist), and 
metoclopramide (dopaminergic antagonist) did 
not show significant change in pain response 
when compared with curcumin (40 mg/kg) group; 
but it showed a significant difference with control 
group (DMSO 5%) (P<0.05) (table 3).
 Discussion                                                                                     
This study showed that curcumin could decrease 
withdrawal syndrome symptoms in a dose 
dependent manner in morphine dependent 
mouse. Our data also show that curcumin activity 
in withdrawal syndrome management is mediated 
by potent antinociceptive effect of this compound. In 
visceral pain induced model, curcumin decreased 
abdominal constrictions (writhing) of mice, which 
were induced with acetic acid. This result showed 
that antinociception effect of curcumin was mediated 
by opioidergic and serotonergic system; as 
confirmed by the results in other studies.24 In order 
to evaluate the effect of this compound in morphine 
dependency, the standard protocol of withdrawal 
syndrome was performed. For the assessment 
of curcumin antinociception activity and possible 
mechanism of its effect, writhing test were studied 
on antagonists of six neurotransmitters that were 
implicated and involved in pain perception. 
Many studies have been carried out on the 
evaluation of brain neurotransmitters. They all 
confirm the critical role of these peptides and 
amines such as dopamine, adrenaline, serotonin, 
histamine and opioids like peptides in pain 
perception and management.5 Additionally, they 
confirm the effect of these neurotransmitters in 
morphine withdrawal syndrome that probably 
anecdote of their impression in morphine and 
other opioids dependency. In many studies 
and pharmacotherapy protocols on the pain of 
withdrawal syndrome, medications that manage 
these neurotransmitters are used.25 In previous 
studies, all compounds and medications that 
were used for the attenuation of withdrawal 
Table 2: Effect of various doses of Curcumin in acetic acid-induced writhing test in mice
Treatment Dose (mg/kg IP) Latency 
Time (sec)
Writhing test Inhibition  
P value (Mean±SEM)
Inhibition % 
    P. value%
P value
Control 10 (ml/kg) 337±40 63±5.1 ------ ------
Curcumin 10 389±50 48±1.7 23 0.0145 vs. control
Curcumin 20 455±26 46±4.6 26 0.0069 vs. control
Curcumin 40 611±21 38±0.4 29 0.0002 vs. control
Indometacin 5 786±66 16±3.1 74 <0.0001 vs. control
N=8 for each group
 
Table 3: Effects of neurotransmitters antagonists on the antinociceptive action of Curcumin (40 mg/kg)
Treatment Dose 
(mg/kg IP)
Latency
Time (sec)
Writhing test 
Inhibition 
P value
(Mean±SEM)
Inhibition % 
P value%
P value
Curcumin 40 614±19 42±0.3 33 0.0002 vs.vehicle
Naloxone+Curcumin 2+40 30±1.6 55±1.8 12 0.0009 vs. curcumin
cyproheptadine+Curcumin 4+40 216±13 53±1 19 0.0045 vs. curcumin
Phentolamine+Curcumin 20+40 603±11 43±0.4 31 0.0003 vs. vehicle
Chlorpheniramine+Curcumin 10+40 605±14 44±0.6 30 0.0005 vs. vehicle
Cimetidine+Curcumin 10+40 600±17 40±1 36 0.0001 vs. vehicle
Metoclopramide+Curcumin 2+40  601±12 46±0.5 26 0.0013 vs. vehicle
Vehicle (DMSO 5%) 10 (ml/kg) 324±34 63±4.2 ------ -----
N=8 for each group
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syndrome were long acting opioidergic and non 
opioidergic drugs. These drugs can increase 
concentration of dopamine, adrenalin, serotonin 
and other neurotransmitters in synaptic space.5 
Previous studies proved the effect of these 
neurotransmitters in pain management.26,27 
In recent years, increased usage of herbal 
compound and traditional medicine in neuronal 
disorder, such as dependency and pain, 
exacerbated the need for identification of their 
mechanisms.28,29 Pervious study demonstrate 
the effect of important compounds of herbal 
medication on the mentioned neurotransmitter 
receptors that mimics their effects.30 Curcumin is 
one of such herbal medicines that several studies 
indicate that it has antinociceptive effects. It is a 
major component of turmeric rhizomes, which 
has important medicinal and pharmacological 
properties. Past studies have demonstrated that 
this fraction can modulate the pain signaling 
pathway in the brain.17,31 In this study, curcumin 
was administrated at doses of 10, 20 and 40 mg/
kg and the severity of morphine dependency was 
measured by naloxone induced precipitated 
withdrawal syndrome. Our study indicates 
that curcumin as a dose dependent manner 
significantly attenuates the withdrawal signs in 
comparison with control positive (dependent) 
mice. In addition, clonidine at the dose of 0.4 
mg/kg, as a standard treatment of morphine 
dependency, causes significant decrease in 
opioid abandonment sign and its severity. Our 
data confirm previous results that clonidine 
is effective in the management of withdrawal 
syndrome.32 Our results also indicates that 
curcumin is effective in attenuating withdrawal 
syndrome in a dose dependent manner. 
Furthermore, there is a significant difference 
between the severity of morphine cessation 
in morphine dependent without treatment and 
morphine dependent under treatment by various 
dosages of curcumin. This difference is more 
potent in the group treated with 40 mg/kg of 
curcumin. The data also suggest that, there 
is no statistical difference between curcumin 
treatment groups and clonidine treatment group. 
It is therefore concluded that curcumin can be 
used as an adjunct or substitute treatment of 
opioid withdrawal syndrome.
Having established the effectiveness of 
curcumin in reducing morphine withdrawal 
syndrome, a study was performed on the possible 
mechanisms involved in morphine abandonment 
induced pain relief in acetic acid induced 
abdominal constriction test. The corresponding 
data indicate that pretreatment with curcumin 
at doses of 10, 20, and 40 mg/kg significantly 
attenuate the count of abdominal constriction 
in comparison with control (saline treatment) 
group. Our data also indicated that there is a 
statistical difference in the count of abdominal 
constriction between curcumin treatment groups 
and indometacin treatment group. Current 
study also confirms previous researches on 
indometacin efficacy in the management of acetic 
acid induced writhing test.33 The data suggest 
that curcumin can be used as adjunct therapy for 
pain relief in combination with indometacin and 
other painkillers. 
It is reported that curcumin has potential 
synergistic effects with NSAIDs and prostaglandin 
producer inhibitors in decreasing orofacial pain in 
rats.19 On the basis of this study, curcumin can 
reduce inflammation and pain mediators. It was 
indicated that curcumin has a potential capability 
for inhibiting the activation of inflammatory 
mediators such as cyclooxygenase-2 (COX-
2), lipoxygenase, and inducible nitric oxide 
synthase products.34 Our data illustrated that 
there are statistical differences between groups 
under treatment with curcumin pretreated with 
naloxone and cyperoheptadine in comparison 
with group under treatment of curcumin alone. 
We can also conclude that pretreatment with 
naloxone and cyperoheptadine decreases 
curcumin antinociception activity. These 
findings are confirmed by the results in other 
studies.16,35 Our results also showed that there 
is no difference between group pretreated with 
phentolamine, chlorpheniramine, cimetidine 
and metoclopramide in comparison with the 
group treated with curcumin alone. Therefore, it 
suggests that curcumin antinociceptive activity 
is not mediated by adrenergic, histaminergic, 
and dopaminergic systems. However, the 
precise mechanisms and signaling pathways of 
curcumin antinociceptive effect remain unclear. 
In the present study, these doses were only 
used in animal models and its effective dose in 
human could be different. We recommend that in 
future studies, the exact mechanism of curcumin 
effects should be evaluated and determined by 
developing molecular methods and clarify its 
molecular and signaling pathways effect. 
 Conclusion                                                                                      
This study demonstrated that curcumin could be 
useful in attenuating the adverse effect of withdrawal 
syndrome. Based on our findings, antinociceptive 
activity of curcumin in a mouse model of visceral 
pain was mediated by opioidergic and serotonergic 
systems that confirms the fact that curcumin has 
opoidergic like activity. Therefore, the usage of 
curcumin could be practically effective in attenuating 
the pain of opioid withdrawal period.
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